Jennifer H Han1,2,3, Ellie J C Goldstein4,5, Jacqueleen Wise2, Warren B Bilker2,3, Pam Tolomeo2, Ebbing Lautenbach1,2,3. 1. Division of Infectious Diseases, Department of Medicine. 2. Center for Clinical Epidemiology and Biostatistics, and. 3. Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia. 4. R.M. Alden Research Laboratory, Culver City, California; and. 5. Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles.
Abstract
BACKGROUND: The rapid emergence of carbapenem-resistant Klebsiella pneumoniae (CRKP) represents a major public health threat, including in the long-term acute care hospital (LTACH) setting. Our objective in this study was to describe the epidemiologic characteristics of CRKP in a network of US LTACHs. METHODS: An observational study was performed among 64 LTACHs from January 2014 to March 2015. Clinical cultures were included, with the first CRKP isolate recovered from each patient per study quarter evaluated. LTACH and geographic area-based CRKP prevalence and clinical and microbiologic characteristics were described. RESULTS: A total of 3846 K. pneumoniae cultures were identified, with an overall carbapenem resistance rate of 24.6%. There were significant differences in CRKP rates across geographic regions, with the highest in the West (42.2%). Of 946 CRKP isolates, 507 (53.6%) were from a respiratory source, 350 (37.0%) from a urinary source, and 9 (9.4%) from blood. Among 821 unique patients with CRKP colonization or infection, the median age was 73 years. There was a high prevalence of respiratory failure (39.8%) and the presence of a central venous catheter (50.9%) or tracheostomy (64.8%). Resistance rates of CRKP isolates were high for amikacin (59.2%) and fluoroquinolones (>97%). The resistance rate to colistin/polymyxin B was 16.1%. CONCLUSIONS: Nearly 25% of K. pneumoniae clinical isolates in a US network of LTACHs were CRKP. Expansion of national surveillance efforts and improved communication among LTACHs and acute care hospitals will be critical for reducing the continued emergence of CRKP across the healthcare continuum.
BACKGROUND: The rapid emergence of carbapenem-resistant Klebsiella pneumoniae (CRKP) represents a major public health threat, including in the long-term acute care hospital (LTACH) setting. Our objective in this study was to describe the epidemiologic characteristics of CRKP in a network of US LTACHs. METHODS: An observational study was performed among 64 LTACHs from January 2014 to March 2015. Clinical cultures were included, with the first CRKP isolate recovered from each patient per study quarter evaluated. LTACH and geographic area-based CRKP prevalence and clinical and microbiologic characteristics were described. RESULTS: A total of 3846 K. pneumoniae cultures were identified, with an overall carbapenem resistance rate of 24.6%. There were significant differences in CRKP rates across geographic regions, with the highest in the West (42.2%). Of 946 CRKP isolates, 507 (53.6%) were from a respiratory source, 350 (37.0%) from a urinary source, and 9 (9.4%) from blood. Among 821 unique patients with CRKP colonization or infection, the median age was 73 years. There was a high prevalence of respiratory failure (39.8%) and the presence of a central venous catheter (50.9%) or tracheostomy (64.8%). Resistance rates of CRKP isolates were high for amikacin (59.2%) and fluoroquinolones (>97%). The resistance rate to colistin/polymyxin B was 16.1%. CONCLUSIONS: Nearly 25% of K. pneumoniae clinical isolates in a US network of LTACHs were CRKP. Expansion of national surveillance efforts and improved communication among LTACHs and acute care hospitals will be critical for reducing the continued emergence of CRKP across the healthcare continuum.
Authors: Sarah Y Won; L Silvia Munoz-Price; Karen Lolans; Bala Hota; Robert A Weinstein; Mary K Hayden Journal: Clin Infect Dis Date: 2011-09 Impact factor: 9.079
Authors: David van Duin; Federico Perez; Susan D Rudin; Eric Cober; Jennifer Hanrahan; Julie Ziegler; Raymond Webber; Jacqueline Fox; Pamela Mason; Sandra S Richter; Marianne Cline; Geraldine S Hall; Keith S Kaye; Michael R Jacobs; Robert C Kalayjian; Robert A Salata; Julia A Segre; Sean Conlan; Scott Evans; Vance G Fowler; Robert A Bonomo Journal: Antimicrob Agents Chemother Date: 2014-05-05 Impact factor: 5.191
Authors: Mary K Hayden; Michael Y Lin; Karen Lolans; Shayna Weiner; Donald Blom; Nicholas M Moore; Louis Fogg; David Henry; Rosie Lyles; Caroline Thurlow; Monica Sikka; David Hines; Robert A Weinstein Journal: Clin Infect Dis Date: 2014-12-23 Impact factor: 9.079
Authors: Todd A Davies; Anne Marie Queenan; Brian J Morrow; Wenchi Shang; Karen Amsler; Wenping He; A Simon Lynch; Chris Pillar; Robert K Flamm Journal: J Antimicrob Chemother Date: 2011-07-20 Impact factor: 5.790
Authors: Michael Y Lin; Rosie D Lyles-Banks; Karen Lolans; David W Hines; Joel B Spear; Russell Petrak; William E Trick; Robert A Weinstein; Mary K Hayden Journal: Clin Infect Dis Date: 2013-08-14 Impact factor: 9.079
Authors: Matthew E Falagas; Giannoula S Tansarli; Drosos E Karageorgopoulos; Konstantinos Z Vardakas Journal: Emerg Infect Dis Date: 2014-07 Impact factor: 6.883
Authors: Teppei Shimasaki; Anna Seekatz; Christine Bassis; Yoona Rhee; Rachel D Yelin; Louis Fogg; Thelma Dangana; Enrique Cornejo Cisneros; Robert A Weinstein; Koh Okamoto; Karen Lolans; Michael Schoeny; Michael Y Lin; Nicholas M Moore; Vincent B Young; Mary K Hayden Journal: Clin Infect Dis Date: 2019-05-30 Impact factor: 9.079
Authors: Jonathan A Otter; Michel Doumith; Frances Davies; Siddharth Mookerjee; Eleonora Dyakova; Mark Gilchrist; Eimear T Brannigan; Kathleen Bamford; Tracey Galletly; Hugo Donaldson; David M Aanensen; Matthew J Ellington; Robert Hill; Jane F Turton; Katie L Hopkins; Neil Woodford; Alison Holmes Journal: Sci Rep Date: 2017-10-05 Impact factor: 4.379